In the phase 2b, dose-ranging ADESOS trial, Prof. Eric Simpson (Oregon Health and Science University, OR, USA) and colleagues randomised 233 adults with moderate-to-severe AD to placebo or one of the orismilast arms at dosages of twice daily 20 mg, 30 mg, or 40 mg for 16 weeks [1].
The 4 study arms were overall balanced at baseline. The cohort included 51% women, and the mean age was 37.0. Of note, the mean Eczema Area and Severity Index (EASI) score was 22.7, 15% of the participants had an IGA indicating severe disease.
At week 16, all dosages of orismilast showed significantly higher rates of IGA 0/1 than placebo in the primary analysis: 26% (20 mg), 24% (30 mg), 31% (40 mg), compared with 10% on placebo (all P<0.05). The picture was not so clear for EASI response. For example, EASI75 response rates were 36% in the placebo arm and 30%, 26%, and 36% in the orismilast arms. “We think it's probably an investigator training issue, because of that variability in EASI score,” Prof. Simpson stated. Looking at the subgroup with severe AD in the 20 mg arm, EASI75 and EASI90 rates were 31% and 12% compared with 21% and 6% on placebo, respectively.
The data for achieving a ≥4-point reduction in the Peak Pruritus Numerical Rating Scale (NRS) started to be significant at week 1 (8% placebo vs 21%, 25%, 32% on orismilast; P<0.05 for all comparisons), which increased to 10% placebo versus 30%, 33%, 34% at week 2. The ≥4-point Skin Pain NRS reduction rates were also statistically significant as of week 1.
No new safety signals were identified. The adverse events known in PDE-4 inhibition like diarrhoea and nausea mainly appeared within the first 4 weeks. In total, 2 serious adverse events occurred on orismilast. “I do feel like these data confirm the relevance of this approach in AD, and we're currently planning phase 3 studies,” Prof. Simpson concluded.
- Simpson E, et al. Orismilast efficacy in adults with moderate-to-severe atopic dermatitis in a phase 2b trial: early impact on itch and patient-reported outcomes. D1T01.1C, EADV Congress 2024, 25–28 September, Amsterdam, the Netherlands.
Copyright ©2024 Medicom Medical Publishers
Medical writing support was provided by Karin Drooff MPH
Posted on
Previous Article
« HS: Bimekizumab shows sustained 2-year efficacy Next Article
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema »
« HS: Bimekizumab shows sustained 2-year efficacy Next Article
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema »
Table of Contents: EADV 2024
Featured articles
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa
Online First
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Second-generation selective PDE-4 inhibitor shows promise in AD
HS: Bimekizumab shows sustained 2-year efficacy
JAK1 inhibitor shows promising long-term efficacy in PN
Deuruxolitinib significantly improves hair satisfaction in alopecia areata
Familial hidradenitis suppurativa associated with higher risk for metabolic disease
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa
Imsidolimab potential future therapeutic avenue for generalised pustular psoriasis
Prurigo nodularis: long-term treatment reduces relapse events
Atopic dermatitis early in life imposes a lifelong psychosocial burden
PsoBest registry: Biologics have become the first choice in moderate-to-severe psoriasis
Topical pan-JAK inhibitor mitigates inflammatory biomarkers in frontal fibrosing alopecia
Atopic hand eczema: similar treatment success for dupilumab and topical delgocitinib
IL-13 inhibitor shows safety and efficacy in AD over 3 years
Semaglutide: also beneficial for patients with HS?
Advanced BCC: histological subtype and time to complete response may predict tumour recurrence
New targets identified for chronic wound healing
Related Articles
April 22, 2024
GUIDE demonstrates: Hit hard and early in psoriasis
April 19, 2019
JAK-inhibitors: an emerging treatment option for vitiligo
October 16, 2023
Nemolizumab shows high success rates in prurigo nodularis
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com